All diseases
Disease workspace
Cardiovascular Disease
Spectrum of atherosclerotic and thrombotic conditions affecting heart and vasculature.
Unmet need
Residual risk despite statins; bleeding vs. thrombosis balance.
Platelet activationLipid metabolismInflammation
Evidence behind this
Confidence score92%
Signal strength: HighLevel 1 (meta-analysis of RCTs)
Evidence grade
Approved
Reduced major vascular events in secondary prevention; primary prevention benefit-risk varies by age.
Mechanism
Irreversible COX-1 inhibition reduces thromboxane A2-mediated platelet aggregation.
clinical trialmeta analysisfda labelMultiple Phase III trials
Authoritative sources
AI-generated summary
Generated March 15, 2026Last verified June 26, 2026
Low-dose aspirin has Level 1 evidence for secondary cardiovascular prevention. Primary prevention guidelines have narrowed due to bleeding risk in lower-risk populations (ASPREE, ARRIVE trials).
Source papers
- Antithrombotic Trialists' Collaboration, Lancet 2002
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.